Blog Archives

Diabetes: No end to SGLT2-inhibitor drugs side effects

01 September 2018 – The American Food and Drug Administration (FDA)  is warning that cases of a very rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Read more ›

Tags: , , , , , , , , , , , , , , , , , , ,

Risk of leg and foot amputations under Canagliflozin (Invokana, Invokamet)

May 17, 2017 – Following up on an earlier Drug Safety Communication from May 2016 and based on new data from two large clinical trials, the American Food & Drug Administration (FDA) has concluded that the type 2 diabetes medicines Canagliflozin (Invokana), Canagliflozin/Metformin (Invokamet),  and Canagliflozin/Metformin (Invokamet XR) cause an increased risk of leg and foot amputations.

Read more ›

Tags: , , , , , , , ,

Sodium-glucose cotransporter-2 (SGLT2) inhibitors in Type-2 Diabetes: Risk of acute kidney injury

June 16, 2016 – The sodium-glucose cotransporter 2 (SGLT2) is a protein that is encoded by the SLC5A2 gene. SGLT2 is one member of a larger family of sodium-glucose cotransporters which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. 

Read more ›

Tags: , , , , , , , , , , , , ,

SGLT2 Inhibitors and ketoacidosis: Warnings about too much acid in the blood and serious urinary tract infections included in new drug labels

December 5, 2015 – A safety review by the American Food and Drug Administration (FDA) has resulted in the addition of specific warnings to the drug labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections.

Read more ›

Tags: , , , , , , , , , , , , , ,

Type 2 Diabetes: Risk for bone fracture and decreased bone mineral density under canagliflozin therapy

 September 12, 2015 – Drug Safety Information: The American Food and Drug Administration (FDA)  has just strengthened the warning for the type 2 diabetes medicines containing  canagliflozin as active ingredient, i.e. Invokana and Invokamet, related to the increased risk of bone fractures, and added new information about decreased bone mineral density in afflicted patients.

Read more ›

Tags: , , , , , , , ,

Medicines based on SGLT2 inhibiton may result in ketoacidosis, a serious condition of too much acid in the blood

May 15, 2015 – The American Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines Canagliflozin (Invokana), Dapagliflozin (Farxiga), and Empagliflozin (Jardiance) may lead to ketoacidosis,

Read more ›

Tags: , , , , , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Ultrapotent antibody mix blocks COVID-19 virus attachment September 25, 2020
    A mix of ultrapotent antibodies from recovered COVID-19 patients has been shown to recognize and lock down the infection machinery of the pandemic coronavirus and keep it from entering cells. Each of the antibody types performs these overlapping tasks slightly differently. A low-dose of the antibodies protected against infection in animal studies.
  • Low level alcohol use during pregnancy can impact child's brain development September 25, 2020
    A new study finds any alcohol use during pregnancy, even low levels, is associated with subtle, yet significant behavioural and psychological effects in children including anxiety, depression and poor attention.
  • An app monitors cancer patients' health status and rewards participation September 25, 2020
    Gamification is becoming increasingly common in educational settings, but can also be used in other fields such as health. Researchers at the Complutense University of Madrid and the University of Zaragoza have developed the Close2U application, which enables healthcare staff to monitor cancer patients' mood and physical discomfort using daily questionnaires. In return for the […]
  • An area of the brain where tumor cells shelter from chemotherapy in childhood leukaemia September 25, 2020
    Sometimes, the central nervous system harbours tumour cells that elude treatment and thus become one of the main sources of relapse. Research led by the Complutense University of Madrid has identified one of these locations in which the cells remain protected: the stroma of the choroid plexus, a structure in the brain ventricles responsible for […]
  • Trends in treatment, survival among women with advanced ovarian cancer September 25, 2020
    This observational study examined survival rates and the use of chemotherapy before surgery among women with advanced-stage epithelial ovarian cancer in the United States from 2004 to 2016.
Top